Form 4: Zevra Therapeutics Director Douglas W. Calder Awarded Stock Options

Director Douglas W. Calder received stock options for 39,200 shares of Zevra Therapeutics, Inc. as compensation for board service.

Summary

• Douglas W. Calder, a director of Zevra Therapeutics, Inc., was granted stock options to purchase 39,200 shares of the company's common stock on May 13, 2024.
• The exercise price of the options is $4.89 per share, which equals the closing price of ZVRA on the Nasdaq Global Select Market on the grant date.
• The options were awarded as compensation for Calder's service on the board of directors, according to the company's non-employee director compensation policy.
• The options vest on the earlier of (i) the first anniversary of the grant date, (ii) one day prior to the first annual meeting of stockholders following the grant date, or (iii) immediately prior to a change in control of the Issuer, subject to continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard compensation practice for a director, indicating confidence in the company's future.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of compensation for directors of publicly traded companies, aligning their interests with shareholders and incentivizing company performance.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary significantly across the pharmaceutical industry depending on company size, stage of development, and board responsibilities.
• Comparing Zevra's director compensation to peers like BioCryst Pharmaceuticals or Catalyst Pharmaceuticals would provide a better understanding of whether the option grant is in line with industry norms.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders' equity if the options are exercised.
• The grant incentivizes the director to act in the best interests of the shareholders.

Key Dates